The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (4 analysts) rates it none, with a mean price target of $50. It reported earnings in this window, a natural checkpoint for the thesis.
HomeTrust Bancshares, Inc.
HTB · the NYSE · USD · Market cap $792M · 577 employees
HomeTrust Bancshares, Inc.
FAIL · Does not pass the screenPrice as of 23 Oct 2026Daily close, not a live quoteLast reviewed 5 days ago
Screened 2026-10-23 · the tape above runs as of 20:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price48.10 USD at the 23 Oct 2026 close
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 2.00)
- Last reviewed23 Oct 2026 (5 days ago)
A summary of the dated readings below, not a live quote and not advice.
What this means: price 48.10 against the desk's fair-value range, base estimate 52.25, over the last year.
- Trend Accumulation
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 2.00, read 2026-10-27
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its accumulation label.
HomeTrust Bancshares, Inc. holds its Accumulation at $48.10. The statistical read favours the sellers, held for 437 days.
| Phase | Accumulation |
| Quantitative state | The statistical read favours the sellers, held for 437 days |
| Price at the screen | $48.10 |
| Valuation | 12.17 trailing · 12.62 forward price to earnings |
| Values screen | FAIL · score 30.0 |
| Beta | 0.81 |
Five Screens, Shown in Full
Does not pass. Prohibited keyword in sector/industry: bank
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Prohibited keyword in sector/industry: bank | Fail |
| Debt load | Excluded | Below 33% | Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. | Fail |
| Interest-bearing cash | Excluded | Below 33% | Interest-bearing cash and securities are of assets, above the one-third limit. | Fail |
| Receivables | Excluded | Below 49% | Money owed to the company is of assets, above the 49% limit. | Fail |
| Revenue purity | Excluded | Below 5% | of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
HomeTrust Bancshares, does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HTB's ethical verdict changes
Today HTB does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 14.0% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus None. The average target sits +5% from the screen price.
Reading the gap · Our model sees value the Street hasn't fully caught up to yet.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 12.6xpriced for continued growth |
| Trailing P/E | 12.2xreasonably valued |
| EPS, trailing | 3.87 |
| EPS, forward | 3.73 |
| Revenue growth | +9.3%steady growth |
| Profit margin | 31.6%highly profitable on every dollar of sales |
| Return on equity | 11.5%a modest return on shareholder capital |
| Dividend yield | 125.00% |
| Beta | 0.81steadier than the market |
| Short interest, float | 0.02% |
| 52-week range | 34.66 - 48.36 |
| Market cap | $792M |
| Employees | 577 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeHTB trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (4 analysts) rates it none, with a mean price target of $50. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (4 analysts) rates it none, with a mean price target of $50. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (4 analysts) rates it none, with a mean price target of $50. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (4 analysts) rates it none, with a mean price target of $50. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (4 analysts) rates it none, with a mean price target of $50. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (4 analysts) rates it none, with a mean price target of $50. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 3.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (4 analysts) rates it none, with a mean price target of $50. It reported earnings in this window, a natural checkpoint for the thesis.
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (4 analysts) rates it none, with a mean price target of $50.
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (4 analysts) rates it none, with a mean price target of $50.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $45.59 | +4.8% | $0.15 | $1,051 | +5.1% |
| 2 months | $45.40 | +5.2% | $0.15 | $1,056 | +5.6% |
| 3 months | $41.91 | +14.0% | $0.15 | $1,144 | +14.4% |
| 6 months | $44.57 | +7.2% | $0.28 | $1,078 | +7.8% |
| 1 year | $36.49 | +30.9% | $0.53 | $1,324 | +32.4% |
| 2 years | $26.61 | +79.6% | $1.00 | $1,833 | +83.3% |
| 3 years | $21.37 | +123.6% | $1.43 | $2,303 | +130.3% |
| 5 years | $26.79 | +78.4% | $2.17 | $1,865 | +86.5% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever HTB does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.